VISEN Pharmaceuticals
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
Overview
A China-focused biopharma company developing long-acting endocrine therapies using TransCon technology.
MetabolicEndocrinologyRare Diseases
Technology Platform
TransCon (Transient Conjugation) technology, a prodrug platform that temporarily inactivates a drug with a carrier-linker for predictable, sustained release of the native, active drug upon injection.
Opportunities
Major opportunity lies in commercializing the first once-weekly growth hormone in China's large pediatric GHD market and expanding into other endocrine indications with improved long-acting therapies that address poor adherence with daily injections.
Risk Factors
Key risks include commercial execution against established daily therapies, achieving favorable National Reimbursement Drug List (NRDL) inclusion in China, and potential future competition from other long-acting formulations.
Competitive Landscape
Competes against daily recombinant human growth hormone (e.g., from Novo Nordisk, Pfizer) in GHD and standard care (calcium/active vitamin D) in hypoparathyroidism; differentiation is superior dosing convenience and potential efficacy/safety profile of its TransCon-based long-acting therapies.